WebDoctor Encyclopedia

Article

Oncolytic Virus Therapy (T-VEC)

What is oncolytic virus therapy?

Oncolytic virus therapy uses viruses that have been modified to infect and destroy cancer cells while largely leaving healthy cells alone. “Oncolytic” means “cancer-dissolving”. The most widely used example is talimogene laherparepvec, usually called T-VEC (brand name Imlygic), which is used to treat melanoma that cannot be removed with surgery.

T-VEC is made from the herpes simplex virus type 1, the virus that causes cold sores. Scientists have changed its genes so that it multiplies mainly in cancer cells and so that it carries an extra gene for an immune-boosting protein called GM-CSF. The virus is injected directly into melanoma deposits in the skin, under the skin or in lymph nodes.

T-VEC works in two ways. First, the virus multiplies inside the cancer cells until they burst and die.

Second, the dying cells release cancer proteins and GM-CSF, which alert the immune system. The immune system can then attack melanoma cells elsewhere in the body, including in deposits that were not injected. This is why T-VEC is considered a type of immunotherapy.

A brief history

Doctors noticed more than a century ago that some people’s tumours shrank after a viral infection. Attempts to use natural viruses to treat cancer in the mid-twentieth century were largely unsuccessful.

Advances in genetic engineering in the 1990s allowed scientists to design safer viruses that targeted cancer cells. T-VEC was developed in the United Kingdom and was approved for melanoma in the United States and Europe in 2015, after the OPTiM trial (Andtbacka et al., 2015). It was the first oncolytic virus approved in Western countries.

1. Key facts at a glance

Feature Details
Type of treatment Immunotherapy (oncolytic virus)
Medicine Talimogene laherparepvec (T-VEC, Imlygic)
Main use Melanoma that cannot be removed by surgery, with deposits in the skin, under the skin or in lymph nodes
How it is given Injected directly into tumours, sometimes guided by ultrasound
Schedule Second dose 3 weeks after the first, then every 2 weeks
Duration Usually at least 6 months, unless other treatment is needed
Main side effects Flu-like symptoms, tiredness, chills, fever, pain at the injection site

2. How it works

Engineering the virus

Change Purpose
Removal of a gene the virus needs in normal cells The virus multiplies mainly in cancer cells
Removal of a gene that hides infected cells from the immune system Helps the immune system recognise infected cancer cells
Addition of the GM-CSF gene Infected cells release GM-CSF, which attracts and activates immune cells

Two ways of attacking the cancer

Effect What happens
Direct killing (oncolysis) The virus multiplies in the cancer cell until the cell bursts
Immune activation Released cancer proteins and GM-CSF train the immune system to target melanoma

Effects beyond the injected tumours

Because the immune system is activated, some tumours that were not injected can also shrink, although the effect is usually strongest in the injected areas. In a trial combining T-VEC with ipilimumab, deposits in internal organs shrank in about half of the people who had them (Chesney et al., 2018).

Why it does not usually make people ill with herpes

The changes to the virus make it much less able to multiply in healthy cells. Most people already carry the natural herpes simplex virus. T-VEC remains sensitive to antiviral medicines such as aciclovir, which can be used if needed, although these would also stop the treatment working.

3. Who it is for

Conditions treated

Condition Role of T-VEC
Melanoma Unresectable melanoma with deposits that can be injected, mainly in skin, under the skin and in lymph nodes
Nodular melanoma When the disease has spread locally or regionally and cannot be removed
Superficial spreading melanoma Same use when spread cannot be removed surgically
Acral lentiginous melanoma Same use; often affects hands and feet

Who is most likely to benefit

Feature Why it matters
Disease mainly in the skin, under the skin and lymph nodes These deposits can be injected
No or limited spread to internal organs Responses are strongest in regional disease
No previous systemic treatment, or limited treatment Responses were higher in untreated people
Good general health Allows regular visits and injections

In Europe, T-VEC is approved for melanoma that has spread regionally or to distant skin and lymph nodes, but not to bone, brain, lung or other internal organs.

Who should not have T-VEC

Situation Reason
Severely weakened immune system Risk of widespread herpes infection
Pregnancy Possible risk to the baby
Living with someone who is severely immunocompromised Precautions may be difficult

Other oncolytic viruses

T-VEC is the oncolytic virus most widely available in Europe and North America. Other oncolytic viruses have been approved in a few countries, for example for brain tumours in Japan and head and neck cancer in China, and many more are being tested in clinical trials. They are based on different viruses, such as adenoviruses, but share the same idea of combining direct killing of cancer cells with immune activation.

4. Before treatment

Step Why it is done
Scans Show where the melanoma is
Mapping of lesions Identify which deposits can be injected
Blood tests General health
Discussion of other options Immunotherapy, targeted therapy, surgery, radiotherapy
Household review Precautions for people you live with
Medicines review Antiviral medicines and steroids can interfere

5. What to expect: step by step

Step What happens
1. Preparation The skin is cleaned; a local anaesthetic may be used
2. Injection T-VEC is injected into one or more tumours
3. Ultrasound Used to guide injection into deeper deposits
4. Dressing Injected sites are covered with an airtight, waterproof dressing
5. Monitoring Briefly, for any reaction
6. Home Usually the same day
7. Repeat Three weeks after the first treatment, then every 2 weeks

Which lesions are injected

At each visit, the doctor decides which deposits to inject, starting with any new or larger lesions. The total amount injected depends on the size of the lesions. Over time, injected deposits may become inflamed, shrink or flatten.

Responses can take time

Tumours sometimes appear to grow or become inflamed before they shrink, because immune cells flood into them. For this reason, treatment is usually continued for at least 6 months unless new disease appears that needs a different treatment.

Combining with other treatments

T-VEC is increasingly studied together with immune checkpoint inhibitors. The idea is that the virus turns injected tumours into a “vaccine” that wakes up the immune system, while the checkpoint inhibitor releases the brakes on immune cells. Trials have shown higher response rates with some combinations, although the best way to use them is still being worked out (Chesney et al., 2018). Your team can tell you whether a combination or a clinical trial is an option.

6. Side effects and risks

Side effect What to expect
Flu-like symptoms Fever, chills and aches, often for a day after injection
Tiredness Common
Injection site pain or redness Common
Nausea Sometimes
Headache Sometimes
Skin infection (cellulitis) Uncommon; treated with antibiotics
Cold sores or herpes infection Uncommon
Loss of skin colour (vitiligo) Occasionally, a sign of immune activation

How common are serious side effects?

In OPTiM, the most common side effects were tiredness, chills and fever. Severe side effects were uncommon; the only severe one affecting at least 2% of people was cellulitis, at about 2% (Andtbacka et al., 2015). Taking paracetamol before and after injections can reduce flu-like symptoms.

Protecting others

Precaution Why
Keep injection sites covered with an airtight dressing Usually for at least a week after each injection, or longer if they weep
Wash hands after touching dressings Prevents spread
Dispose of dressings in sealed bags As instructed by your team
Avoid contact between injected sites and others Especially pregnant women, babies and people with weak immune systems
Use condoms during sex Reduces any risk of passing on the virus

7. Results and outlook

Study Main finding
OPTiM trial, 436 patients Lasting responses were seen in 16.3% with T-VEC versus 2.1% with GM-CSF injections, and median survival was 23.3 versus 18.9 months (Andtbacka et al., 2015)
OPTiM final analysis About 17% of people treated with T-VEC had complete disappearance of all visible melanoma, and most of these were still alive 5 years later (Andtbacka et al., 2019)
T-VEC with ipilimumab, 198 patients Responses were seen in 39% with the combination versus 18% with ipilimumab alone (Chesney et al., 2018)

What the results mean

T-VEC can produce long-lasting responses in a minority of people, particularly those with disease in the skin and lymph nodes and those who have not had other treatments (Andtbacka et al., 2015). For many people today, immune checkpoint inhibitors are the first choice, and T-VEC is used for selected people or in combination within clinical trials.

8. Recovery and aftercare

Tip Why
Take paracetamol as advised Eases flu-like symptoms
Rest after treatment Tiredness is common
Keep dressings in place Protects others and the wound
Watch for redness spreading from a site Could be infection
Report cold sores, eye pain or blisters Could signal herpes infection
Protect skin from the sun Melanoma risk and treated skin sensitivity

Caring for injection sites

Injected deposits can become sore, crusted or ulcerated as they respond. Keep them covered, change dressings as instructed and keep the skin around them clean and moisturised. Wear gloves when changing dressings if your team advises it. Tell your nurse if a site becomes very painful, smells unpleasant or starts to bleed, as dressings and pain relief can be adjusted.

Follow-up

You are seen at every treatment visit, and scans are done every few months. Photographs of the skin deposits are often taken to track changes.

Living with advanced melanoma

Advanced melanoma treatment has changed greatly, and many people now live for years with good quality of life. Skin cancer nurses, support groups and psychological support can help with the uncertainty and practical challenges of ongoing treatment.

9. Alternatives

Alternative When it is considered
Immune checkpoint inhibitors First-line treatment for most advanced melanoma
BRAF and MEK inhibitors Melanoma with a BRAF mutation
Surgery When deposits can be removed
Palliative radiotherapy Painful or bleeding deposits
Isolated limb perfusion or electrochemotherapy Many skin deposits on a limb
Clinical trials Newer oncolytic viruses and combinations

10. Frequently asked questions

Question Answer
Will I get cold sores? It is uncommon, but report any blisters
Can I hug my family? Yes, but keep injected areas covered and avoid contact with them
Can I work? Many people work, though the day after injection can be tiring
Does it treat melanoma inside the body? Mainly injected areas, but sometimes other areas respond too
Is it a cure? It can lead to long-lasting responses in some people
Can I take antiviral tablets? Not routinely, as they may stop the treatment working
Will I need a hospital stay? No, treatment is given as an outpatient
Can I have T-VEC if I have had cold sores? Yes; previous cold sores do not prevent treatment
How long is each visit? Usually less than an hour

11. Questions to ask your care team

  • Am I suitable for T-VEC, and why is it recommended over other options?
  • Which lesions will be injected?
  • How long will treatment last?
  • What precautions should I take at home?
  • How will we know if it is working?
  • Could T-VEC be combined with other immunotherapy?

Resources

  1. Andtbacka, R.H. et al. (2015) ‘Talimogene laherparepvec improves durable response rate in patients with advanced melanoma’, Journal of Clinical Oncology, 33(25), pp. 2780-2788.
  2. Andtbacka, R.H.I. et al. (2019) ‘Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma’, Journal for ImmunoTherapy of Cancer, 7(1), p. 145.
  3. Chesney, J. et al. (2018) ‘Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma’, Journal of Clinical Oncology, 36(17), pp. 1658-1667.
  4. National Cancer Institute (2026) Talimogene Laherparepvec. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/talimogenelaherparepvec (Accessed: October 2026).
  5. National Cancer Institute (2026) Melanoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.